PURPOSE: We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer. EXPERIMENTAL DESIGN: Eligible patients had stage IV colorectal adenocarcinoma, and had not received prior chemotherapy for metastatic disease. Each cycle consisted of 14 days. Cycle 1 consisted of oxaliplatin, leucovorin, and 5-FU (FOLFOX-4). All subsequent cycles consisted of FOLFOX-4 with gefitinib at 500 mg orally daily throughout the 14-day cycle. RESULTS: Forty-five patients were enrolled and were assessable for toxicity. Forty-three patients were assessable for response. Thirty-one of the 43 patients (72%) had either a complete or partial response by the Response Evaluation Criteria in Solid Tumors. Median overall survival was 20.5 months. Median time to progression was 9.3 months. Commonly encountered grade 3 or 4 toxicities included diarrhea in 67% of patients and neutropenia in 60%. Grade 2 acneiform skin rash typical of gefitinib occurred in 60% of patients. CONCLUSIONS: IFOX is an active first-line regimen in patients with metastatic colorectal adenocarcinoma, showing higher response rates but also increased toxicities compared with FOLFOX-4 alone in a similar patient population.
PURPOSE: We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer. EXPERIMENTAL DESIGN: Eligible patients had stage IV colorectal adenocarcinoma, and had not received prior chemotherapy for metastatic disease. Each cycle consisted of 14 days. Cycle 1 consisted of oxaliplatin, leucovorin, and 5-FU (FOLFOX-4). All subsequent cycles consisted of FOLFOX-4 with gefitinib at 500 mg orally daily throughout the 14-day cycle. RESULTS: Forty-five patients were enrolled and were assessable for toxicity. Forty-three patients were assessable for response. Thirty-one of the 43 patients (72%) had either a complete or partial response by the Response Evaluation Criteria in Solid Tumors. Median overall survival was 20.5 months. Median time to progression was 9.3 months. Commonly encountered grade 3 or 4 toxicities included diarrhea in 67% of patients and neutropenia in 60%. Grade 2 acneiform skin rash typical of gefitinib occurred in 60% of patients. CONCLUSIONS:IFOX is an active first-line regimen in patients with metastatic colorectal adenocarcinoma, showing higher response rates but also increased toxicities compared with FOLFOX-4 alone in a similar patient population.
Authors: Marie C Prewett; Andrea T Hooper; Rajiv Bassi; Lee M Ellis; Harlan W Waksal; Daniel J Hicklin Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: T André; M A Bensmaine; C Louvet; E François; V Lucas; F Desseigne; K Beerblock; O Bouché; E Carola; Y Merrouche; F Morvan; G Dupont-André; A de Gramont Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Roy S Herbst; Anne-Marie Maddox; Mace L Rothenberg; Eric J Small; Eric H Rubin; Jose Baselga; Federico Rojo; Waun Ki Hong; Helen Swaisland; Steven D Averbuch; Judith Ochs; Patricia Mucci LoRusso Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: S Cascinu; R Berardi; S Salvagni; G D Beretta; V Catalano; F Pucci; A Sobrero; P Tagliaferri; R Labianca; M Scartozzi; F Crocicchio; E Mari; A Ardizzoni Journal: Br J Cancer Date: 2007-12-04 Impact factor: 7.640
Authors: Wells A Messersmith; Antonio Jimeno; Heather Jacene; Ming Zhao; Piotr Kulesza; Daniel A Laheru; Yasmin Kahn; Alexander Spira; Janet Dancey; Christine Iacobuzio-Donahue; Ross C Donehower; Michael Carducci; Michelle A Rudek; Manuel Hidalgo Journal: Clin Colorectal Cancer Date: 2010-12 Impact factor: 4.481
Authors: Markus Moehler; Thomas Thomaidis; Chourouk Zeifri; Tareq Barhoom; Jens Marquardt; Philippe Ploch; Joern Schattenberg; Annett Maderer; Carl Christoph Schimanski; Arndt Weinmann; Marcus Alexander Woerns; Anne L Kranich; Jens M Warnecke; Peter Robert Galle Journal: J Cancer Res Clin Oncol Date: 2014-09-19 Impact factor: 4.553
Authors: Nise H Yamaguchi; Ingrid A Mayer; Artur Malzyner; Carlos Jc de Andrade; Andre M Murad; Auro Del Giglio; Venancio Alves Journal: J Gastrointest Oncol Date: 2014-02